Read + Share
. Correction to: P0722 Efficacy and Safety of Risankizumab in Patients With
Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label
Long-Term Extension. J Crohns Colitis 2025;19:jjaf045.
PMID: 40147003
|
 |
|
. Correction to: P0722 Efficacy and Safety of Risankizumab in Patients With
Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label
Long-Term Extension. J Crohns Colitis 2025;19:jjaf045.
PMID: 40147003
|
|
|
|